Olumiant® is the commercial brand name of Baricitinib Tablets, an orally active selective Janus kinase (JAK) inhibitor developed by Eli Lilly. It selectively inhibits JAK1 and JAK2, regulates multiple pro-inflammatory cytokine signaling pathways, and suppresses persistent inflammatory responses. Main IndicationsTreatment…
Firmagon® is the commercial brand name of Degarelix Acetate for Injection, a subcutaneously administered gonadotropin-releasing hormone (GnRH) antagonist developed by Ferring Pharmaceuticals. It competitively blocks GnRH receptors in the pituitary gland, rapidly suppresses luteinizing hormone and follicle-stimulating hormone secretion, lowers…
Otezla® is the commercial brand name of Apremilast Tablets, an orally active phosphodiesterase 4 (PDE4) inhibitor developed by Amgen. It inhibits PDE4 to modulate intracellular cyclic adenosine monophosphate levels, regulates the balance of pro-inflammatory and anti-inflammatory mediators, and alleviates inflammatory…
Nubeqa® is the commercial brand name of Darolutamide Tablets, an orally active novel androgen receptor inhibitor developed by Bayer. It competitively binds to androgen receptors, blocks receptor nuclear translocation and DNA binding, suppresses androgen-driven signaling pathways and inhibits proliferation of…
Erleada® is the commercial brand name of Apalutamide Tablets, an orally active next-generation androgen receptor inhibitor developed by Janssen. It binds competitively to androgen receptors, inhibits androgen receptor nuclear translocation and DNA binding, and blocks androgen-mediated oncogenic signaling to suppress…
Faslodex® is the commercial brand name of Fulvestrant Injection, a selective estrogen receptor degrader (SERD) developed by AstraZeneca. It competitively binds to estrogen receptors, accelerates the degradation of estrogen receptors, blocks estrogen-driven oncogenic signaling, and inhibits proliferation of hormone receptor-positive…
Phesgo® is the official global commercial brand name, and Hishuangyi is its Chinese brand developed by Roche. It is a fixed-dose combination subcutaneous formulation of pertuzumab and trastuzumab. The two monoclonal antibodies bind to different epitopes of HER2 receptor, block…
Xpovio® is the official global commercial brand name, and Xiweiao is its Chinese brand name developed by Karyopharm and exclusively commercialized by Dizal Pharma. It is an oral selective inhibitor of nuclear export (SINE). It selectively blocks exportin 1 (XPO1),…
Tibsovo® is the official global commercial brand name, and Tuoshuwo is its Chinese brand name co-developed by CSPC and Servier. It is an oral selective mutant IDH1 enzyme inhibitor. It targets mutated isocitrate dehydrogenase 1, blocking abnormal oncometabolite 2-HG accumulation,…
Halaven® is the official global commercial brand name, and Hailewei is its Chinese brand name developed by Eisai. It is an intravenous non-taxane microtubule dynamics inhibitor. It suppresses microtubule polymerization and promotes tubulin depolymerization, blocking mitosis and triggering apoptosis in…